A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04855747 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

236

Enrollment

INDUSTRY

Sponsor class

Stopped Program Discontinued

Conditions

Major Depressive Disorder
Depression

Interventions

DRUG: REL-1017
DRUG: Placebo

Sponsor

Levomecor Inc.